- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves combination suspension for glaucoma
The FDA has approved Simbrinza suspension (Alcon) for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.
Basel, Switzerland-The FDA has approved Simbrinza suspension (Alcon) for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.
The medication is a fixed-dose combination that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21% to 35%. In addition, it is the only available, fixed-dose combination therapy for glaucoma in the United States that does not contain a beta blocker.
“Given its excellent efficacy, established safety profile, and the fact that it is the only available fixed-dose combination without a beta blocker approved in the United States, Simbrinza has the potential to re-shape the treatment paradigm for glaucoma,” said Robert Warner, area president, United States and Canada for Alcon.
The new ophthalmic suspension is a fixed-dose combination of a carbonic anhydrase inhibitor (brinzolamide 1.0%) and an alpha-2 adrenergic receptor agonist (brimonidine tartrate 0.2%) combined into one multi-dose bottle.
For more articles in this issue of Ophthalmology Times eReport, click here.
